Global Lyme Disease Diagnostics Market 2021 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Lyme Disease Diagnostics Market 2021 (Includes Business Impact of COVID-19)
Global Lyme Disease Diagnostics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global lyme disease diagnostics market report has been segmented on the basis of diagnostic technology, end user, and region.
Request Covid - 19 Impact
The global Lyme Disease Diagnostics market size was valued at USD $1.40 billion in 2020 and is projected to reach USD $2.22 billion by 2030, and is anticipated to expand at a CAGR of 5.25% over the forecast period from 2020 to 2030.


Global Lyme Disease Diagnostics Market: Overview


Lyme disease is an infectious disease that is caused by the bacteria species Borrelia burgdorferi sensu lato. It is transmitted to humans by a bite from an infected deer tick or black-legged. People living in wooded areas are more likely to suffer from lyme diseses illness. Lyme disease symptoms include headache, fatigue, fever, and skin rash. Laboratory evaluation is appropriate for patients who are suffering from various other diseases such as neurologic, cardiac symptoms associated with Lyme disease, or arthritic. In the diagnostic tests, it detects antibodies produced by the immune system in response to the infection.


Global Lyme Disease Diagnostics Market: Dynamics


Growing prevelance of lyme disease is a key factor expected to drive the growth of the target market. In addition, increasing number of cases of tick borne infectious diseases, rising incidences of new types of vector borne diseases, rising health care expenditure are some of the factors expected to drive growth of the global lyme disease diagnostics market

However, lack of awareness in underdeveloped and developing region regarding diagnosis of lyme diseases are the factors expected to hamper the growth of the target market to some extent.


Global Lyme Disease Diagnostics Market: Segment Analysis


Among the diagnostic technology segments, serological test is expected to register high revenue growth over the forecast years, due to wide application of various types of blood tests for diagnoses of various disease conditions. Among the end user segments, the hospital is expected to register highest CAGR over the forecoming years and is expected to dominate the market. This is primarily attributed to, available of commercial test kits for detection of lyme diseases.


Global Lyme Disease Diagnostics Market: Trends


Key trend witnessed in the target market are, various government organizations and private/public institutes such as National Institute of Allergy and Infectious Diseases (NIAID) are working towards enlightening of lyme disease diagnostics across the globe. Several research institutes are collaboration with CDC, NIAID and are focusing towards development of new improved methods for lyme disease screening in patients.


Global Lyme Disease Diagnostics Market: Regional Analysis


In 2018, the markets in North America is expected to dominate in the target market over the next ten years. This is primarily attributed to increasing initiatives of government and private institutes for treatment and diagnosing of lyme diseases in countries in the region. In addition, Centres for Disease Control and Prevention, estimated that around 300,000 people suffered from lyme disease each year. The market in Asia Pacific is expected to gain market growth during the forecast years, due to rising prevelance of lyme diseases. In addition, increasing demand for better diagnostic tests for the disease is increasing as well as novel development of more accurate test of lyme diseases for proper diagnosis and treatment.

Global Lyme Disease Diagnostics Market Segmentation:

Segmentation by diagnostic technology:

  
Serological Test
  
Urine Antigen Tests
  
Lymphocytic Transformation Test
  
Immunofluorescent Staining
  
Nucleic acid Test

Segmentation by end user:

  
Hospitals
  
Public/Private Laboratories
  
Physicians Office


Key Market Players included in the report:


  
Abbott Laboratories
  
Affymetrix Inc.
  
Alere Inc.
  
Baxter International Inc.
  
Bio-Rad Laboratories, Inc.
  
Boulder Diagnostics Inc.
  
Cenogenics Corporation
  
Ceres Nanosciences, Inc.
  
Covance Inc.
  
DiaSorin S.p.A.
  
Galaxy Diagnostics
  
GlaxoSmithKline Pharmaceuticals Ltd.
  
Graphene Frontiers, LLC
  
IGeneX, Inc.
  
Immunetics Inc.
  
Lyme Diagnostics Ltd.
  
Oxford Immunotec plc (Boulder Diagnostics)
  
PerkinElmer, Inc.
  
QIAGEN
  
Quest Diagnostics
  
Roche Diagnostics International Ltd.
  
Siemens AG
  
T2 Biosystems, Inc.
  
Thermo Fisher Scientific, Inc.
  
Trinity Biotech plc


Below are the key development related to Lyme Disease Diagnostics Market in 2020 and 2021.


April  2021: QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis. The LIAISON® LymeDetect® assay is a solution for the early diagnosis of Lyme Borreliosis combining detection of IgG and IgM Antibodies and cellular immunity
The test is available in countries accepting the CE Mark and is designed to be run on the DiaSorin LIAISON® XL and LIAISON® XS platforms. In clinical studies, the assay showed, within 21 days from the first evidence of infection, a sensitivity of 74% versus that of existing, established methods at 49%, while also demonstrating a high diagnostic specificity of 100%. QIAGEN is responsible for product development and manufacturing, while DiaSorin is responsible for global commercialization of the new solution. Source